LivingGLP1
Study S000617

Exenatide Once Weekly for Smoking Cessation: A Randomized Clinical Trial

Registration

Registration
NCT02975297
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE1; PHASE2
Masking
TRIPLE
Status
COMPLETED
Enrollment
84
Start
2016-07
Primary completion
2020-01-03
Lead sponsor
The University of Texas Health Science Center, Houston
Conditions
Smoking Cessation
Interventions
DRUG:Exenatide; DRUG:NRT; BEHAVIORAL:Counseling; DRUG:Placebo
Results posted
TRUE
Individual participant data sharing
NO
Secondary identifiers
OTHER:CCTS Research Scholar Award

Registered primary outcomes

  • Number of Participants Who Self-Reported Abstinence and Who Were Biochemically Verified as Abstinent Via Expired CO Level of ≤ 5ppm [6 weeks]
  • Post-quit Craving as Assessed by the Questionnaire of Smoking Urges [6 weeks]
  • Withdrawal Symptoms as Assessed by the Wisconsin Smoking Withdrawal Scale [6 weeks]
  • Cue-induced Craving for Cigarettes Following Virtual Reality Exposure as Assessed by the Questionnaire of Smoking Urges [1 week]
  • Cue-induced Craving for Cigarettes Following Virtual Reality Exposure as Assessed by the Questionnaire of Smoking Urges [3 weeks]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0008332Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: A Pilot Randomized Controlled Trial.
Yammine L, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
2021Randomized trialPMID 33831213DOIcites ClinicalTrials.gov:NCT02975297; registry reference DERIVED:33831213
R0020868Exenatide once weekly for smoking cessation: study protocol for a randomized clinical trial.
Yammine L, Medicine
2018ProtocolPMID 29480848DOIregistry reference BACKGROUND:29480848